| Features: |
| 9247- | ISO, IH, | capec, | Isorhamnetin augments the anti-tumor effect of capecitabine through the negative regulation of NF-κB signaling cascade in gastric cancer |
| - | vitro+vivo, | GC, | NA |
| 9255- | ISO, IH, | Isorhamnetin Modulates Drug-Resistance-Related Biomarkers in Colon Cancer Cells |
| - | in-vitro, | Colon, | SW48 | - | in-vitro, | CRC, | HT-29 |
| 9254- | ISO, IH, | Isorhamnetin: what is the in vitro evidence for its antitumor potential and beyond? |
| - | Review, | Var, | NA |
| 9253- | ISO, IH, | Progress in the antitumor molecular mechanisms of Isorhamnetin |
| - | Review, | Var, | NA |
| 9252- | ISO, IH, | Isorhamnetin: Reviewing Recent Developments in Anticancer Mechanisms and Nanoformulation-Driven Delivery |
| - | Review, | Var, | NA |
| 9251- | ISO, IH, | Advances in Isorhamnetin Treatment of Malignant Tumors: Mechanisms and Applications |
| - | Review, | Var, | NA |
| 9250- | ISO, IH, | Absorption, excretion and metabolite profiling of methyl-, glucuronyl-, glucosyl- and sulpho-conjugates of quercetin in human plasma and urine after ingestion of onions |
| - | Study, | Nor, | NA |
| 9249- | ISO, IH, | Isorhamnetin alleviates cisplatin-induced acute kidney injury via enhancing fatty acid oxidation |
| - | in-vivo, | Nor, | NA |
| - | in-vitro, | Lung, | A549 |
| 9239- | ISO, IH, | Isorhamnetin suppresses colon cancer cell growth through the PI3K‑Akt‑mTOR pathway |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Colon, | SW480 |
| 9246- | ISO, IH, | Isorhamnetin inhibits migration and promotes apoptosis via modulation of oxidative stress, mitochondrial dysfunction, and the TIGIT/CD155 axis in 4T1 breast cancer cells |
| - | in-vitro, | BC, | 4T1 |
| 9245- | ISO, IH, | Autophagy inhibition enhances isorhamnetin‑induced mitochondria‑dependent apoptosis in non‑small cell lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 9244- | ISO, IH, | Isorhamnetin inhibits bladder cancer progression by mediating glycolysis through targeting the SRC/PI3K/Akt axis |
| - | in-vitro, | Bladder, | 5637 |
| 9243- | ISO, IH, | Isorhamnetin Inhibits Reactive Oxygen Species-Dependent Hypoxia Inducible Factor (HIF)-1α Accumulation |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT-29 |
| 9242- | ISO, IH, | Isorhamnetin Induces Melanoma Cell Apoptosis via the PI3K/Akt and NF- κ B Pathways |
| - | vitro+vivo, | Melanoma, | B16-BL6 |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 9240- | ISO, IH, | Isorhamnetin inhibits cell proliferation and induces apoptosis in breast cancer via Akt and mitogen‑activated protein kinase kinase signaling pathways |
| - | in-vitro, | BC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:519 Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid